Pulmonary Complications of Immunotherapy

Brett C Bade; Jennifer D Possick

doi:10.1016/j.ccm.2020.02.012

Pulmonary Complications of Immunotherapy

Clin Chest Med. 2020 Jun;41(2):295-305. doi: 10.1016/j.ccm.2020.02.012.

Authors

Brett C Bade¹, Jennifer D Possick²

Affiliations

¹ Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, PO Box 208057, 300 Cedar Street TAC - 441 South, New Haven, CT 06520-8057, USA.
² Department of Internal Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, PO Box 208057, 300 Cedar Street, New Haven, CT 06510-8057, USA. Electronic address: jennifer.possick@yale.edu.

PMID: 32402364
DOI: 10.1016/j.ccm.2020.02.012

Abstract

Immune checkpoint inhibitor (ICI) therapy represents a paradigm shift in the treatment of patients with locally advanced and metastatic lung cancer. Although immunotherapy generally has a more favorable safety profile when compared with chemotherapy, immune-related adverse events represent important, but incompletely understood, treatment-limiting complications associated with significant morbidity and mortality risk. Current guidelines for diagnosis and management are derived from consensus experience, highlighting that further prospective investigation in this area is needed. As ICI-related pneumonitis is a clinically and radiographically diverse toxidrome, clinical vigilance is important while treating patients with lung cancer.

Keywords: Immune checkpoint inhibitors; Immunotherapy; Lung cancer; PD-1; PD-L1; Pneumonitis; Pulmonary toxicity.

Publication types

Review

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / pharmacology
Humans
Immunotherapy / adverse effects*
Lung / pathology*
Lung Neoplasms / complications*
Lung Neoplasms / drug therapy

Substances

Antineoplastic Agents, Immunological